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Advances in human genomics are now being effectively applied to the search for host factors underlying
susceptibility to common diseases. From the steady stream of studies showing association of host genetic
factors with viral diseases, it has become clear that host factors contribute substantially to the variability of
viral infections in humans. Candidate gene studies that seek to show associations between single-nucleotide
polymorphisms (SNPs) with a disease outcome have predominated, but whole-genome association studies
(GWAS) have recently appeared. A major goal of these studies is to understand how human genetic variation
contributes to individual differences in susceptibility and to exploit this knowledge for targeted drug devel-
opment.As informative as genetic association
studies have been, they are limited to the
discovery of genomic variation that modify
an observable phenotype. Recently, small
interfering (si) RNA has been used to
silence gene expression and thereby iden-
tify genes important in various biological
pathways—thus adding an important
new tool for the discovery of genes under-
pinning human diseases. The identifica-
tion of genes involved in host defenses
against viral pathogens or required by viral
pathogens for infection, replication, and
pathogenesis will require a variety of
methodologies. I will discuss and com-
pare the relative merits and limitations of
complementary strategies using genetic
genome-wide association and siRNA
functional scans to discover genetic fac-
tors involved in viral pathogenesis.
Consistent with the global impact of
human immunodeficiency virus (HIV)-1 in-
fection, HIV-1 is the most studied human
virus from a host genetic prospective.
For more than a decade, HIV-1 infection
has been under intense scrutiny for un-
derlying genetic factors that modulate
infection susceptibility, control of replica-
tion, and disease outcomes. Results of
host candidate gene studies for acquired
immune deficiency syndrome (AIDS)
were rapidly put into pharmaceutical
service. The near-absolute restriction of
HIV-1 infection in homozygotes for a 32
base-pair deletion in CCR5 rapidly led to
the development of several inhibitors ofCCR5 to prevent HIV cell entry (Rusconi
et al., 2007). The CCR5 D32 mutation in-
troduces a premature stop codon result-
ing in a truncated protein that cannot be
utilized by HIV for cell entry, thus blocking
infection in individuals with two copies of
CCR5 D32 and slowing progression to
AIDS in carriers for this mutation (Agrawal
et al., 2007; Dean et al., 1996). An exam-
ple of personalized medicine was recently
demonstrated in the prevention of a po-
tentially fatal hypersensitivity reaction to
Abacavir, a nucleoside analog reverse
transcriptase inhibitor used to treat
AIDS, by avoiding the drug in carriers of
the human leukocyte antigen (HLA)
B*5701 allele (Mallal et al., 2008). Numer-
ous genetic factors that modify HIV infec-
tion and pathogenesis have been identi-
fied by candidate gene analysis (O’Brien
and Nelson, 2004)—these include genes
encoding HLA class I antigen presenta-
tion molecules, chemokines and their re-
ceptor genes involved in HIV-1 cell entry,
natural killer cell immunoglobin-like
receptors (KIR) genes, cytokines and their
receptors that modulate immune re-
sponse, and the intrinsic viral restriction
factors TRIM5 and APOBEC3G (An
et al., 2004; Javanbakht et al., 2006).
These gene groups were already very
much under the lamplight, as being pre-
dicted as having a role in HIV-1.
The GWAS approach now offers a full
look at the genome to find factors not pre-
viously suspected of influencing viral in-Cell Host & Micfection. High-density genotyping arrays
containing 500K to 1000K features are
now available for screening variation in
the human genome for any disease with
enough cases for adequate statistical
power. It is notable that GWAS studies
of several important diseases have re-
vealed unexpected disease risk factors
that likely would not have been discov-
ered by other approaches. Variation asso-
ciated with diseases has been discovered
in genes not predicted to have a role (e.g.,
age-related macular degeneration with
complement factor H) (Edwards et al.,
2005) as well as in chromosomal regions
devoid of genes (e.g., prostate cancer
with chromosome 8q24) (Yeager et al.,
2007). Understanding the biological
mechanisms underlying many of these
associations may prove to be a difficult
challenge; however, these studies do indi-
cate the unbiased power of GWAS to
identify genomic regions and genes
worthy of further investigation.
HIV-1 and AIDS are again in the lead
with the first report of a GWAS for an
infectious disease (Fellay et al., 2007).
Using the Illumina 550K chip, SNPs were
tested for genetic associations between
viral load (VL) and rate of progression to
CD4 T cell depletion. This study identified
nine SNPs that fell below or very close to
the genome-wide significance of p = 9.3 3
109, a very conservative bar for asso-
ciation. Two SNPs within the HLA region
were associated with host control of VLrobe 3, April 2008 ª2008 Elsevier Inc. 203
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sion. At first glance this study
was disappointing—the
strongest association with
VL was a SNP tracking HLA
B*5701—a well-investigated
allele with solid epidemiologi-
cal and functional support for
its role as a HIV-1 restriction
factor (Migueles et al., 2000).
However, the SNP occurred
within the HCP5 gene, in
near-absolute linkage dis-
equilibrium (LD) with HLA
B*5701, encoding a human
endogenous retroviral ele-
ment with homology to retro-
viralpolgenes—itself a poten-
tial candidate for an HIV-1
restriction gene. In a recent
study of a very small group
of elite controllers who main-
tained undetectable VL,
none carried the HCP5 poly-
morphism, and only 4 of 16
were positive for the protec-
tive allele associated withHLA-C (Han et al., 2008). This study sug-
gests that other, as yet undetected, ge-
netic factors are also required for control
of replication. The GWAS also implicated
for the first time theHLA C locus in control
of VL—possibly extending the role of the
HLA system in adaptive and innate im-
munity. However, given the extensive LD
within the HLA region, disentangling true
causal genes from those tagging along
through LD will likely prove challenging.
A second analysis of rate of progres-
sion using either time to treatment initia-
tion or time of the drop of CD4 cells below
350 revealed seven associated SNPs
that implicated two genes, one of which,
ZNRD1, encodes a RNA polymerase 1
subunit and is a plausible candidate. Curi-
ously, there was no overlap between
genes affecting VL and genes affecting
progression. Given the reported relation-
ship between VL and progression to
AIDS, this is a surprising result (Mellors
et al., 2007); however, it may reflect bias
introduced by patient selection. The pa-
tients for VL were selected based on the
stability of VL over three time points,
whereas the progression group was
selected based on patients’ having at
least four CD4 determinations. This may
have had the unintended consequence
of missing rapid progressors who may204 Cell Host & Microbe 3, April 2008 ª2008have lacked the required four CD4 deter-
minations. These types of biases are
avoided in prospective natural history
cohorts.
What is most remarkable is what was
not reported—only one of the previously
implicated candidate genes (HLA*B5701)
met the bar for statistical significance.
CCR5, a gene critical for HIV-1 infection,
was not detected at all. Although GWAS
have the potential to discover new genes,
this power is limited by the difficulties
imposed by the enormous number of
statistical tests—virtually guaranteeing
that many true associations will be missed
in the avoidance of false-positive associa-
tions. Undoubtedly, there are other true
associations yet to be discovered given
that there were over 350 SNPs with
unexpectedly low p values. Agnostic
approaches considering only p values
will certainly miss many important genes.
Pangenomic approaches incorporating
data from functional and expression data-
bases, as well as virus-mediated changes
in gene expression, will be required to fully
interpret the results of GWAS (Ge et al.,
2008). I expect that the genotype-pheno-
type data from this and other GWAS will
be mined for hypothesis-driven analyses
of biologically plausible potential candi-
dates.If this first GWAS was
underwhelming in its results,
the recent siRNA genome-
wide functional scan revealed
previously unsuspected path-
ways co-opted by HIV (Brass
et al., 2008). The elegant use
of siRNA to knock out one
by one more than 21,000
genes in a human cancer cell
line that supported HIV infec-
tion and replication revealed
273 genes. The cells’ ability
to support HIV-1 replication
and establish new infection
was assessed in a two-stage
assay system sensitive to
both early and late events in
the viral life cycle. Of these
HIV dependency factors
(HDF) required for infection
and replication, only 37 had
previously been identified
(Figure 1). Thus in a single
stroke siRNA identified over
270 potential cellular targets
for drug development. Since
Figure 1. The Impact of the HIV-1 siRNA Genome-wide Functional
Study of HIV-1 Replication on Knowledge of HIV-AIDS-Associated
Genes
The small slice at the top represents genes identified by genetic association
studies; the rest of the circle represents the HIV genes newly identified by
the siRNA study. Categories of genes are identified by color; it is notable that
only association studies detect genes associated with host defenses. Numbers
are approximate; data from the siRNA study are from Brass et al. (2008).Elsevier Inc.none of these HDF was required for cell vi-
ability, they are excellent targets for antivi-
ral drugs—and unlike viral targets that can
develop escape mutations, host targets
are genetically stable. Causal polymor-
phisms in any of these HDF may explain
the variation observed in populations in
HIV replication and susceptibility to infec-
tions. Indeed, the siRNA study identified
ZNRD1 as an HDF, and SNPs in LD with
the ZNRD1 gene were associated with
delayed progression in the GWAS. No
doubt there are other HDF that were not
immediately identified by the GWAS due
to the very conservative bar for signifi-
cance. The identification of these depen-
dency genes underlying cellular pathways
required by HIV and perhaps other mem-
bers of the lentivirus subclass opens new
avenues for basic and translation re-
search. Their contribution to the variance
observed in human populations will
come from detailed genetic interrogation
of these implicated genes.
What are the lessons for future studies
for other viral pathogens? Each method
has limitations and strengths. Where
a workable cellular viral replication model
is available, the siRNA approach seems
more direct for identifying essential host
factors, but developing these cell models
may prove difficult. This method also is
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to systemic (e.g., host defense) factors
(Figure 1). By the design of Brass et al.
(2008), silencing of genes that might
suppress viral replication were not de-
tected—thus the roles of intrinsic antiviral
factors such as TRIM5 or APOBEC3G
were not assessed. Special strengths of
siRNA are that the method detects factors
even in the absence of genetic polymor-
phism, and that the identified gene prod-
ucts, having been shown to be essential
for viral replication but not for host cell
viability, are immediate potential targets
for antiviral drugs. On the other hand,
siRNA scans provide no information on
the population impact of dependency
gene polymorphism, if any, since attribut-
able and relative risks cannot be calcu-
lated without directly testing the effects
of polymorphism in a population.
The immediate strength of genetic epi-
demiological studies is that the effects of
genetic polymorphism are observable in
the natural history of the infection; how-
ever, the results of any single study re-
quire replication to avoid the pitfall of false
discovery. Candidate and genome-wide
association studies have been extremely
robust in identifying host defense factors
and cell surface receptors required for
cell adhesion and entry, but less efficient
at identifying viral dependency factors
(Figure 1). This may be because immune
defense genes and receptors co-opted
by pathogens are under continuing
selective pressure and tend to be highly
variable. Indeed, the discoveries of
knockout mutations resulting in altered
receptors used by HIV-1 (Dean et al.,
1996), norovirus (Lindesmith et al.,
2003), and Plasmodium vivax (Miller
et al., 1976) that restrict infection and the
genetic dissection of the role of HLA
in viral disease point to the success of
association studies.It is important to point out that both the
GWAS and siRNA studies used viral infec-
tion and viral replication as primary
endpoints; however, HIV/AIDS and other
viral diseases are complex. Infection and
replication are just two aspects of an
interactive process involving a number of
biological systems and pathways that
both support and respond to infections
(Rodriguez et al., 2006).
As genome scan methodology using
both functional siRNA and genetic associ-
ation approaches are combined with
expression and functional SNP data now
available in a multitude of public data-
bases (Ge et al., 2008), the pace of dis-
covery host factors interacting with viral
pathogens will quicken. We can hope for
a rapidly increasing use of this knowledge
to improve clinical care and diagnostics
as well as devise therapeutic agents that
target host factors.
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